Statistically significant improvements observed across clinical endpoints; final cohort results expected in Q2 2025 ...

Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be ...

Topas Therapeutics today announced that it will present clinical Phase 2a data on its lead candidate, TPM502, in celiac ...

Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolutionRecruitment stopped early due to positive exploratory and efficacy outcomesPreparations ...

Gosselies, Belgium Saturday, April 26, 2025, 16:00 Hrs [IST] ...

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment ...

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be ...

Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral RinsePhase 2a Study Now Fully Enrolled ...

NeOnc Technologies (NTHI) announced that it expects full enrollment in its Phase 2a clinical trial for its lead therapeutic candidate, ...

today announced positive interim data from the open-label portion of its Phase 2a clinical trial, CLEER-001, evaluating HT-001 for the treatment of pruritus associated with skin toxicities ...

The topline readout from our Phase 2a clinical trial in celiac disease validates the potential of this new drug modality and its potential to address a broad range of immune-mediated indications ...